The product is the real deal. I think CYDY has great potential, but I've based my valuations and investment decisions on what I believe Leronlimab is worth not the effectivenes of management. It is hard to see how it doesn't get approved for combo HIV by FDA at this point. They just need to get the BLA submitted and get the clock ticking towards approval. That will set the company on the path to credibility.

That is what is so frustrating about the BLA delays. I'm less worried about getting to revenue and more interested in reaching credibility. Obviously BTD for cancer would deliver a stunning amount of credibility in an instant.

I think it is very possible that CYDY's management fails to fully capture all the potential of leronlimab for shareholders but they would have to really screw up to not capture at least 2-3 billion.